Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Случай успешной терапии нилотинибом (Тасигной) пациентки с Ph-позитивным хроническим миелолейкозом в хронической фазе с резистентностью к интерферону и Гливеку
Случай успешной терапии нилотинибом (Тасигной) пациентки с Ph-позитивным хроническим миелолейкозом в хронической фазе с резистентностью к интерферону и Гливеку
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Hochhaus A, Drucker BJ, Larson RA. IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood. 2007; 110 (11): 25.
2. Silver RT, Talpaz M, Sawyers CL et al. Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. Blood 2004; 104 (11): 23.
3. O’Brien SG, Gulihot F, Larson R.A et al. IRIS nvestigetors. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994–1004.
4. Kantarjian H, Sawyers C., Hochhaus A et al. International STI 571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9): 645–52.
5. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leucemia. 2004; 18(8):1321–31.
6. Kantarjian HM, Larson RA, Gulihot F et al. J. Declining rates of adverse events (AEs), rare occurrence of serios AEs (SAEs), and unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib in the internationalrandomised study of interferon vs STI571(IRIS). Poster, ASH 2006.
7. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy. Leucemia 2002; 16(11): 2190–6.
8. Brandford S, Hughes T. Detection of Bcr-Abl mutations and resistance to imatinib mesylate. Methods Mol Med 2006; 125:93–106.
9. Jiang X., Zhao Y, Smith C et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to Bcr-Abl targeted therapies. Leucemia 2007; 21:926–35.
10. Soverini S, Martinell G, Rosti G et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid leukemia. J Clin Oncol 2005; 23(18): 4100–9.
11.Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN 107, a selective inhibitors of wild-type and mutant Bcr-Abl. Cancer Cell 2005; 7:129–41.
12. Nagar B, Bornman WG, Pellicena P et al. Crystal structures of the kinase domain c-abl in complex with the small molecule ingibitors PD 173955 and imatinib (STI-571)Cancer Res 2002; 62(15): 4236–43.
13. Kantarjian HM, Hochhaus A, Cortes J et al. Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance. Blood; 2007; 110 (11): 226a (abs. 735).
14. Cortes J, Jabbour E, Hochhaus A et al. Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP). Blood 2007; 110 (11): 315a (abstr. 1040).
2. Silver RT, Talpaz M, Sawyers CL et al. Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. Blood 2004; 104 (11): 23.
3. O’Brien SG, Gulihot F, Larson R.A et al. IRIS nvestigetors. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994–1004.
4. Kantarjian H, Sawyers C., Hochhaus A et al. International STI 571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9): 645–52.
5. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leucemia. 2004; 18(8):1321–31.
6. Kantarjian HM, Larson RA, Gulihot F et al. J. Declining rates of adverse events (AEs), rare occurrence of serios AEs (SAEs), and unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib in the internationalrandomised study of interferon vs STI571(IRIS). Poster, ASH 2006.
7. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy. Leucemia 2002; 16(11): 2190–6.
8. Brandford S, Hughes T. Detection of Bcr-Abl mutations and resistance to imatinib mesylate. Methods Mol Med 2006; 125:93–106.
9. Jiang X., Zhao Y, Smith C et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to Bcr-Abl targeted therapies. Leucemia 2007; 21:926–35.
10. Soverini S, Martinell G, Rosti G et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid leukemia. J Clin Oncol 2005; 23(18): 4100–9.
11.Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN 107, a selective inhibitors of wild-type and mutant Bcr-Abl. Cancer Cell 2005; 7:129–41.
12. Nagar B, Bornman WG, Pellicena P et al. Crystal structures of the kinase domain c-abl in complex with the small molecule ingibitors PD 173955 and imatinib (STI-571)Cancer Res 2002; 62(15): 4236–43.
13. Kantarjian HM, Hochhaus A, Cortes J et al. Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance. Blood; 2007; 110 (11): 226a (abs. 735).
14. Cortes J, Jabbour E, Hochhaus A et al. Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP). Blood 2007; 110 (11): 315a (abstr. 1040).
Авторы
Н.А.Афанасьева, Г.А.Гусарова
Гематологический научный центр РАМН, отделение химиотерапии лейкозов и патологии эритрона, Москва
Гематологический научный центр РАМН, отделение химиотерапии лейкозов и патологии эритрона, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.